Scope

EDCTP2 aims to contribute to the reduction of the social and economic burden of poverty-related diseases (PRDs) in developing countries, in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions for PRDs in partnership with sub-Saharan Africa.

PRDs covered by EDCTP

In EDCTP PRDs include HIV/AIDS, malaria, tuberculosis and the following neglected infectious diseases(NIDs): dengue; rabies; human African trypanosomiasis (sleeping sickness); Leishmaniases; cysticercosis/ taeniasis; dracunculiasis (guinea-worm disease); echinococcosis; foodborne trematodiases; lymphatic filariasis; onchocerciasis (river blindness); schistosomiasis; soil-transmitted helminthiases; Buruli ulcer; leprosy (Hansen disease); trachoma; yaws; diarrhoeal infections; lower respiratory infections; as well as emerging infectious diseases of particular relevance for Africa, such as Ebola.

The programme supports clinical trials and related research activities on PRDs, as well as capacity development for clinical trials and related research in sub-Saharan Africa. EDCTP2 supports all phases of clinical trials (phases I to IV) for new or improved medical interventions, as well as advanced testing and field validation of new diagnostic tools.

Scope_EDCTP

EDCTP2 supported activities

  • Multicentre clinical trials that are performed by research consortia involving both European and African research teams, with capacity building and networking elements integrated
  • Capacity support activities that strengthen the enabling environment for conducting clinical trials and clinical research
  • Fellowships that focus on the career development of individual researchers or clinical staff